title: Troglitazone not only reduced insulin resistance but also improved myotonia in a patient with myotonic dystrophy.
authors: First Department of Internal Medicine, Neurological Institute, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors: K
authors: K
authors: Kashiwagi
authors: S
authors: S
authors: Nagafuchi
authors: N
authors: N
authors: Sekiguchi
authors: A
authors: A
authors: Yamagata
authors: I
authors: I
authors: Iwata
authors: H
authors: H
authors: Furuya
authors: M
authors: M
authors: Kato
authors: Y
authors: Y
authors: Niho
mesh_terms: D000328:Adult; D002839:Chromans / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D009223:Myotonic Dystrophy / Q000188:drug therapy*; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D016896:Treatment Outcome; D000077288:Troglitazone
chemical_list: D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone